[
  {
    "id": "safety-kymriah-crs-001",
    "text_summary": "Cytokine release syndrome (CRS) was the most common serious adverse event in the ELIANA pivotal trial (NCT02435849) of tisagenlecleucel in pediatric/young adult r/r B-ALL. CRS occurred in 77% of patients (any grade), with 46% experiencing grade 3-4 CRS per the Penn Grading Scale. Median onset was day 3 post-infusion (range 1-22 days) with median duration of 8 days. High tumor burden (>50% marrow blasts) and higher peak CAR-T expansion correlated with severe CRS (PMID: 29385376).",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade (77%); Grade 3-4 (46%)",
    "onset_timing": "Median day 3 post-infusion (range 1-22 days)",
    "incidence_rate": "77% any grade, 46% grade 3-4",
    "management_protocol": "Tocilizumab 8 mg/kg IV for grade 2+ CRS; corticosteroids (dexamethasone 10 mg IV q6h) for tocilizumab-refractory cases; ICU monitoring for hemodynamic instability",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2018
  },
  {
    "id": "safety-yescarta-crs-002",
    "text_summary": "In the ZUMA-1 pivotal trial (NCT02348216) of axicabtagene ciloleucel for r/r large B-cell lymphoma, CRS occurred in 93% of patients, with 13% experiencing grade 3+ events per the Lee criteria. Median onset was day 2 (range 1-12 days) with median duration of 7 days. Peak IL-6, ferritin, and CRP levels correlated with CRS severity. Two patients (2%) required vasopressor support. CRS resolved in all patients (PMID: 28187985).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade (93%); Grade 3+ (13%)",
    "onset_timing": "Median day 2 post-infusion (range 1-12 days)",
    "incidence_rate": "93% any grade, 13% grade 3+",
    "management_protocol": "Tocilizumab per institutional CRS management algorithm; corticosteroids for refractory CRS; siltuximab considered for tocilizumab-refractory cases",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2017
  },
  {
    "id": "safety-tecartus-crs-003",
    "text_summary": "Brexucabtagene autoleucel (Tecartus) demonstrated CRS in 91% of patients with r/r mantle cell lymphoma in the ZUMA-2 trial (NCT02601313). Grade 3+ CRS occurred in 15% of patients. Median time to onset was 2 days (range 1-13 days) and median duration was 11 days. One patient experienced grade 5 CRS. Management with early tocilizumab and bridging therapy optimization reduced severe CRS in an updated safety cohort (PMID: 32511981).",
    "product": "Tecartus (brexucabtagene autoleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade (91%); Grade 3+ (15%)",
    "onset_timing": "Median day 2 post-infusion (range 1-13 days)",
    "incidence_rate": "91% any grade, 15% grade 3+",
    "management_protocol": "Tocilizumab for grade 2+; dexamethasone for refractory CRS; bridging corticosteroids prior to infusion to reduce tumor burden",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2020
  },
  {
    "id": "safety-breyanzi-crs-004",
    "text_summary": "Lisocabtagene maraleucel (Breyanzi) showed a favorable CRS profile in the TRANSCEND NHL 001 trial (NCT02631044) for r/r large B-cell lymphoma. CRS occurred in 42% of patients (any grade) with only 2% grade 3+ events per ASTCT consensus grading. The lower CRS rate compared to other CD19-targeted CAR-T products is attributed to the defined CD4:CD8 composition and separate manufacturing of T-cell subsets. Median onset was day 5 (range 1-14 days) (PMID: 33049860).",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade (42%); Grade 3+ (2%)",
    "onset_timing": "Median day 5 post-infusion (range 1-14 days)",
    "incidence_rate": "42% any grade, 2% grade 3+",
    "management_protocol": "Tocilizumab for persistent grade 2 or grade 3+ CRS; supportive care and antipyretics for grade 1; defined CD4:CD8 composition contributes to lower baseline CRS risk",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2021
  },
  {
    "id": "safety-abecma-crs-005",
    "text_summary": "Idecabtagene vicleucel (Abecma) targeting BCMA for r/r multiple myeloma demonstrated CRS in 84% of patients in the KarMMa trial (NCT03361748). Grade 3+ CRS occurred in 5% of patients per ASTCT grading criteria. Median onset was day 1 (range 1-12 days) with median duration of 5 days. CRS in BCMA-targeted CAR-T tends to present earlier than CD19-targeted products. Elevated baseline LDH and high tumor burden were predictive of grade 3+ CRS (PMID: 33626253).",
    "product": "Abecma (idecabtagene vicleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade (84%); Grade 3+ (5%)",
    "onset_timing": "Median day 1 post-infusion (range 1-12 days)",
    "incidence_rate": "84% any grade, 5% grade 3+",
    "management_protocol": "Tocilizumab 8 mg/kg IV for grade 2+; corticosteroids for refractory cases; close hemodynamic monitoring in first 72 hours due to early onset pattern",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2021
  },
  {
    "id": "safety-carvykti-crs-006",
    "text_summary": "Ciltacabtagene autoleucel (Carvykti) targeting BCMA demonstrated CRS in 95% of patients in the CARTITUDE-1 trial (NCT03548207) for heavily pretreated r/r multiple myeloma. Grade 3-4 CRS occurred in 4% of patients. Median time to onset was 7 days (range 1-12 days), notably later than other BCMA CAR-T products, attributed to the dual-epitope binding design. Median CRS duration was 4 days. All CRS events resolved with tocilizumab and/or corticosteroids (PMID: 35658469).",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade (95%); Grade 3-4 (4%)",
    "onset_timing": "Median day 7 post-infusion (range 1-12 days)",
    "incidence_rate": "95% any grade, 4% grade 3-4",
    "management_protocol": "Tocilizumab per ASTCT guidelines; corticosteroids for refractory CRS; later onset allows outpatient monitoring in select patients after initial observation period",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2022
  },
  {
    "id": "safety-kymriah-icans-007",
    "text_summary": "Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 39% of patients receiving tisagenlecleucel in the ELIANA trial, with 13% grade 3-4 events. ICANS typically presented concurrent with or following CRS, with median onset on day 6. Manifestations included encephalopathy, confusion, aphasia, and somnolence. Higher pre-infusion disease burden and peak serum IL-6 levels were associated with ICANS severity. ICE score monitoring was implemented per ASTCT consensus guidelines (PMID: 29385376).",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "ICANS",
    "severity_grade": "Any grade (39%); Grade 3-4 (13%)",
    "onset_timing": "Median day 6 post-infusion",
    "incidence_rate": "39% any grade, 13% grade 3-4",
    "management_protocol": "ICE score monitoring q8h; dexamethasone 10 mg IV q6h for grade 2+; high-dose methylprednisolone 1 g IV for grade 3+; anti-seizure prophylaxis with levetiracetam",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2018
  },
  {
    "id": "safety-yescarta-icans-008",
    "text_summary": "ICANS was particularly prevalent with axicabtagene ciloleucel in ZUMA-1, occurring in 64% of patients with 28% grade 3+ events, the highest neurotoxicity rate among approved CD19 CAR-T products. Severe cases included cerebral edema in 1% of patients. ICE score decline and elevated CSF protein were early indicators. Endothelial activation with blood-brain barrier disruption, measured by elevated angiopoietin-2:angiopoietin-1 ratio, is a key pathogenic mechanism (PMID: 29440070).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "ICANS",
    "severity_grade": "Any grade (64%); Grade 3+ (28%)",
    "onset_timing": "Median day 5 post-infusion (range 1-17 days)",
    "incidence_rate": "64% any grade, 28% grade 3+",
    "management_protocol": "ICE score monitoring q4-8h; dexamethasone 10 mg IV q6h for grade 2; high-dose methylprednisolone for grade 3+; intrathecal therapy considered for refractory cases; seizure prophylaxis mandatory",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2017
  },
  {
    "id": "safety-tecartus-icans-009",
    "text_summary": "ICANS occurred in 63% of patients treated with brexucabtagene autoleucel in ZUMA-2, with 31% grade 3+ events. Three patients (3%) developed grade 5 neurologic events. The high ICANS rate in MCL may reflect disease-specific factors including CNS involvement. Prophylactic corticosteroids during lymphodepletion and early intervention with dexamethasone were associated with reduced grade 3+ ICANS in a protocol-amended safety cohort (PMID: 32511981).",
    "product": "Tecartus (brexucabtagene autoleucel)",
    "event_type": "ICANS",
    "severity_grade": "Any grade (63%); Grade 3+ (31%)",
    "onset_timing": "Median day 7 post-infusion (range 1-23 days)",
    "incidence_rate": "63% any grade, 31% grade 3+",
    "management_protocol": "ICE score monitoring q4h; prophylactic dexamethasone on days 0-2; aggressive early intervention with corticosteroids for grade 2; anakinra considered for steroid-refractory cases",
    "outcome": "resolved with sequelae",
    "reporting_source": "pivotal_trial",
    "year": 2020
  },
  {
    "id": "safety-breyanzi-icans-010",
    "text_summary": "Lisocabtagene maraleucel demonstrated a lower ICANS rate in TRANSCEND NHL 001, with 30% any-grade and 10% grade 3+ neurotoxicity. The defined-composition product with separate CD4+ and CD8+ CAR-T cell components may contribute to reduced neurotoxicity. Median onset was day 8 post-infusion. No fatal neurotoxic events were observed. ICANS resolved in all patients within a median of 5 days (PMID: 33049860).",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "event_type": "ICANS",
    "severity_grade": "Any grade (30%); Grade 3+ (10%)",
    "onset_timing": "Median day 8 post-infusion (range 2-19 days)",
    "incidence_rate": "30% any grade, 10% grade 3+",
    "management_protocol": "ICE score monitoring q8-12h; dexamethasone for grade 2+; supportive care with anti-seizure prophylaxis; lower baseline risk allows extended outpatient monitoring",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2021
  },
  {
    "id": "safety-abecma-icans-011",
    "text_summary": "ICANS with idecabtagene vicleucel in KarMMa occurred in 18% of patients (any grade), with 3% grade 3+ events. Neurotoxicity was generally mild and self-limited in BCMA-targeted CAR-T compared to CD19-targeted products, potentially due to lower CNS inflammatory response. Movement and neurocognitive adverse events distinct from classical ICANS were reported in 3% of patients and are under ongoing investigation (PMID: 33626253).",
    "product": "Abecma (idecabtagene vicleucel)",
    "event_type": "ICANS",
    "severity_grade": "Any grade (18%); Grade 3+ (3%)",
    "onset_timing": "Median day 2 post-infusion (range 1-10 days)",
    "incidence_rate": "18% any grade, 3% grade 3+",
    "management_protocol": "ICE score monitoring; dexamethasone for grade 2+; corticosteroids for grade 3+; neurological evaluation for atypical presentations including movement disorders",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2021
  },
  {
    "id": "safety-carvykti-icans-012",
    "text_summary": "ICANS was reported in 17% of patients receiving ciltacabtagene autoleucel in CARTITUDE-1, with 2% grade 3-4 events. However, a unique delayed neurotoxicity pattern was identified in 5% of patients, presenting 3-8 weeks post-infusion with cranial nerve palsies, peripheral neuropathy, and parkinsonian-like features distinct from acute ICANS. This non-ICANS neurotoxicity led to an FDA class-wide safety investigation and label updates (PMID: 35658469).",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "event_type": "ICANS",
    "severity_grade": "Any grade (17%); Grade 3-4 (2%)",
    "onset_timing": "Acute ICANS: median day 8; delayed neurotoxicity: 3-8 weeks post-infusion",
    "incidence_rate": "17% any grade ICANS, 2% grade 3-4; 5% delayed neurotoxicity",
    "management_protocol": "ICE score monitoring for acute ICANS; extended neurological follow-up for 8+ weeks; MRI brain for delayed symptoms; corticosteroids and IVIG for delayed neurotoxicity",
    "outcome": "resolved with sequelae",
    "reporting_source": "pivotal_trial",
    "year": 2022
  },
  {
    "id": "safety-yescarta-cytopenia-013",
    "text_summary": "Prolonged cytopenias (lasting >30 days post-infusion) are a major post-market safety concern for all CAR-T products. In real-world data from the CIBMTR registry for axicabtagene ciloleucel, grade 3-4 neutropenia persisted beyond day 30 in 33% of patients, thrombocytopenia in 29%, and anemia in 17%. Prolonged cytopenias were associated with prior lines of therapy (>3), severe CRS, and baseline cytopenias pre-lymphodepletion (PMID: 34407410).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "cytopenia",
    "severity_grade": "Grade 3-4",
    "onset_timing": "Persisting beyond day 30 post-infusion; biphasic pattern with initial recovery then late relapse",
    "incidence_rate": "33% prolonged neutropenia, 29% prolonged thrombocytopenia, 17% prolonged anemia (>30 days)",
    "management_protocol": "G-CSF for neutropenia (avoid in first 21 days due to potential CRS exacerbation); TPO-receptor agonists for refractory thrombocytopenia; transfusion support; bone marrow biopsy if persistent >90 days",
    "outcome": "resolved",
    "reporting_source": "registry",
    "year": 2021
  },
  {
    "id": "safety-kymriah-cytopenia-014",
    "text_summary": "In long-term follow-up of the ELIANA trial, prolonged cytopenias were observed in 49% of pediatric patients at day 28. By 3 months, 24% still had grade 3-4 cytopenias. Tisagenlecleucel fludarabine/cyclophosphamide lymphodepletion contributed to myelosuppression. A biphasic cytopenia pattern was described: initial recovery by day 14-21 followed by a secondary nadir at day 28-42 correlating with peak CAR-T expansion. Growth factor support improved neutrophil recovery (PMID: 30428784).",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "cytopenia",
    "severity_grade": "Grade 3-4",
    "onset_timing": "Biphasic: initial nadir day 0-14, secondary nadir day 28-42; 24% persistent at 3 months",
    "incidence_rate": "49% at day 28, 24% persistent at 3 months",
    "management_protocol": "G-CSF (filgrastim 5 mcg/kg/day) after day 21; platelet and RBC transfusion support; infection prophylaxis with antibacterials and antifungals during neutropenia",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2019
  },
  {
    "id": "safety-abecma-cytopenia-015",
    "text_summary": "Cytopenias are the most common adverse event with idecabtagene vicleucel, with grade 3-4 neutropenia in 89%, thrombocytopenia in 52%, and anemia in 60% during KarMMa. Prolonged cytopenias (>1 month) were particularly notable in multiple myeloma patients due to extensive prior therapy including alkylators and immunomodulatory agents. Hematopoietic reserve assessed by pre-lymphodepletion CBC and bone marrow cellularity predicted prolonged cytopenia risk (PMID: 33626253).",
    "product": "Abecma (idecabtagene vicleucel)",
    "event_type": "cytopenia",
    "severity_grade": "Grade 3-4",
    "onset_timing": "Onset during lymphodepletion; 37% with grade 3+ at day 30",
    "incidence_rate": "89% grade 3-4 neutropenia, 52% grade 3-4 thrombocytopenia, 60% grade 3-4 anemia overall",
    "management_protocol": "G-CSF after day 14; TPO-receptor agonists (eltrombopag) for persistent thrombocytopenia; transfusion thresholds: platelets <10K, hemoglobin <7 g/dL; marrow evaluation at day 60 if unresolved",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2021
  },
  {
    "id": "safety-carvykti-cytopenia-016",
    "text_summary": "In CARTITUDE-1, ciltacabtagene autoleucel caused grade 3-4 neutropenia in 95%, thrombocytopenia in 68%, and anemia in 44%. Prolonged hematologic toxicity (>2 months) occurred in 41% of patients. The heavily pretreated myeloma population (median 6 prior lines) had limited marrow reserve. Two deaths attributed to prolonged cytopenias with secondary infections were reported. Extended cytopenia duration correlated with number of prior lines and baseline platelet count <75,000/mcL (PMID: 35658469).",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "event_type": "cytopenia",
    "severity_grade": "Grade 3-4",
    "onset_timing": "Onset during lymphodepletion; 41% with prolonged cytopenias >2 months",
    "incidence_rate": "95% grade 3-4 neutropenia, 68% grade 3-4 thrombocytopenia, 44% grade 3-4 anemia",
    "management_protocol": "G-CSF from day 14; aggressive antimicrobial prophylaxis during prolonged neutropenia; transfusion support; consideration of autologous stem cell boost for persistent aplasia >90 days",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2022
  },
  {
    "id": "safety-yescarta-infection-017",
    "text_summary": "Infections are a leading cause of non-relapse mortality post-CAR-T therapy. In a multicenter real-world analysis of axicabtagene ciloleucel recipients (n=238), infections occurred in 48% of patients within the first 90 days: bacterial (29%), viral (23%), and fungal (8%). Invasive fungal infections (Aspergillus, Candida) occurred predominantly during prolonged neutropenia. Infection-related mortality was 4.6%. Hypogammaglobulinemia (IgG <400 mg/dL) was present in 43% and associated with 2.3-fold higher infection risk (PMID: 34543381).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "infection",
    "severity_grade": "Grade 3-4",
    "onset_timing": "Peak incidence days 0-30; ongoing risk through 12 months post-infusion",
    "incidence_rate": "48% any infection within 90 days; 8% invasive fungal; 4.6% infection-related mortality",
    "management_protocol": "Antimicrobial prophylaxis: levofloxacin, acyclovir/valacyclovir, fluconazole/posaconazole; PJP prophylaxis with TMP-SMX; IVIG replacement for IgG <400 mg/dL; CMV and EBV monitoring",
    "outcome": "resolved",
    "reporting_source": "post_marketing",
    "year": 2021
  },
  {
    "id": "safety-kymriah-infection-018",
    "text_summary": "In the ELIANA long-term follow-up, 43% of pediatric patients experienced infections within 8 weeks of tisagenlecleucel infusion. Serious infections (grade 3+) occurred in 24%. Respiratory viruses (RSV, influenza, parainfluenza) were the most common viral pathogens. B-cell aplasia, a pharmacodynamic effect of CD19 CAR-T, leads to persistent hypogammaglobulinemia requiring IgG replacement therapy. Vaccination with inactivated vaccines is recommended starting 6 months post-infusion, though efficacy may be reduced (PMID: 30428784).",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "infection",
    "severity_grade": "Any grade (43%); Grade 3+ (24%)",
    "onset_timing": "43% within 8 weeks; ongoing risk due to B-cell aplasia",
    "incidence_rate": "43% any infection within 8 weeks, 24% grade 3+",
    "management_protocol": "Antimicrobial prophylaxis per institutional guidelines; IVIG 400 mg/kg monthly for IgG <400 mg/dL; revaccination schedule beginning 6 months post-CAR-T; avoid live vaccines indefinitely",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2019
  },
  {
    "id": "safety-abecma-infection-019",
    "text_summary": "Infection complications with idecabtagene vicleucel are compounded by the immunosuppressed state of heavily pretreated multiple myeloma patients. In KarMMa, grade 3+ infections occurred in 22% of patients. Opportunistic infections included Pneumocystis jirovecii (1.5%), CMV reactivation (5%), and herpes zoster (8%). Hepatitis B reactivation screening is mandatory prior to lymphodepletion. Prophylactic antimicrobials are recommended for a minimum of 6 months post-infusion (PMID: 33626253).",
    "product": "Abecma (idecabtagene vicleucel)",
    "event_type": "infection",
    "severity_grade": "Grade 3+ (22%)",
    "onset_timing": "Ongoing risk for 6-12 months post-infusion",
    "incidence_rate": "22% grade 3+ infections; 5% CMV reactivation; 8% herpes zoster",
    "management_protocol": "Acyclovir prophylaxis for VZV/HSV; TMP-SMX for PJP prophylaxis; HBV screening and entecavir if HBsAg+; weekly CMV PCR monitoring for 3 months",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2021
  },
  {
    "id": "safety-breyanzi-infection-020",
    "text_summary": "COVID-19 emerged as a significant infectious complication in post-market CAR-T safety data. A multicenter analysis of 77 CAR-T recipients (including Breyanzi patients) with SARS-CoV-2 infection showed 25% mortality, compared to 3% in the general population. Prolonged viral shedding (median 40 days) and impaired seroconversion due to B-cell aplasia complicated management. COVID-19-directed monoclonal antibodies and nirmatrelvir/ritonavir showed benefit. Tixagevimab/cilgavimab pre-exposure prophylaxis was recommended (PMID: 35354230).",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "event_type": "infection",
    "severity_grade": "Grade 3-5",
    "onset_timing": "Variable; risk persists beyond 12 months due to B-cell aplasia",
    "incidence_rate": "25% mortality in CAR-T recipients with COVID-19; prolonged viral shedding median 40 days",
    "management_protocol": "Pre-exposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies; nirmatrelvir/ritonavir or remdesivir for acute infection; extended antiviral courses due to impaired clearance; IVIG supplementation",
    "outcome": "resolved with sequelae",
    "reporting_source": "post_marketing",
    "year": 2022
  },
  {
    "id": "safety-kymriah-secmalig-021",
    "text_summary": "In November 2023, FDA issued a class-wide safety communication regarding T-cell malignancies (including CAR-positive T-cell lymphomas) in patients who received BCMA- or CD19-directed CAR-T products. Through FAERS, 22 cases of T-cell malignancies were identified across all products, some with CAR transgene detected in the malignant T cells by PCR. The FDA updated all CAR-T product labels with a boxed warning for secondary T-cell malignancies. Estimated incidence is <1% based on ~34,000 patients treated globally (FDA Safety Communication, November 2023).",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "secondary_malignancy",
    "severity_grade": "Grade 3-5",
    "onset_timing": "Median 19 months post-infusion (range 2-60 months)",
    "incidence_rate": "<1% based on ~34,000 treated globally; 22 FAERS cases across all products as of November 2023",
    "management_protocol": "Long-term monitoring with CBC and peripheral blood flow cytometry; lymph node evaluation for unexplained lymphadenopathy; PCR for CAR transgene in suspected malignant T cells; report to FDA MedWatch",
    "outcome": "fatal",
    "reporting_source": "FAERS",
    "year": 2023
  },
  {
    "id": "safety-yescarta-secmalig-022",
    "text_summary": "Post-marketing surveillance identified cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) following axicabtagene ciloleucel therapy. In ZUMA-1 long-term follow-up, therapy-related MDS/AML occurred in 5.5% of patients, though causality is confounded by prior alkylator and platinum exposure. CAR transgene was not detected in MDS/AML blasts, suggesting these are therapy-related rather than insertional mutagenesis events. Annual bone marrow assessment is recommended for patients with persistent cytopenias (PMID: 34543240).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "secondary_malignancy",
    "severity_grade": "Grade 3-5",
    "onset_timing": "6-36 months post-infusion; median 14 months",
    "incidence_rate": "5.5% therapy-related MDS/AML in ZUMA-1 long-term follow-up",
    "management_protocol": "Annual CBC with differential; bone marrow biopsy for persistent unexplained cytopenias; cytogenetics and FISH panel for MDS-associated abnormalities; referral to leukemia service if confirmed",
    "outcome": "ongoing",
    "reporting_source": "pivotal_trial",
    "year": 2022
  },
  {
    "id": "safety-carvykti-secmalig-023",
    "text_summary": "The FDA boxed warning for T-cell malignancies was specifically prompted by early cases identified in BCMA-directed CAR-T recipients. Among ciltacabtagene autoleucel recipients, cases of CAR-positive T-cell lymphoma were confirmed with integration site analysis demonstrating lentiviral insertion near oncogenic loci. The CARTITUDE-1 updated safety analysis reported a cumulative secondary malignancy rate of 14% at median 27.7-month follow-up, including 10% MDS/AML and individual cases of T-cell lymphoma. Ongoing FDA REMS monitoring is required (PMID: 37713520).",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "event_type": "secondary_malignancy",
    "severity_grade": "Grade 3-5",
    "onset_timing": "3-24 months post-infusion for T-cell malignancies; 6-36 months for MDS/AML",
    "incidence_rate": "14% cumulative secondary malignancies at 27.7-month follow-up; <1% CAR-positive T-cell lymphoma",
    "management_protocol": "Lifelong monitoring for secondary malignancies per REMS; peripheral blood flow cytometry q6 months; bone marrow biopsy for unexplained cytopenias; integration site analysis if T-cell malignancy suspected",
    "outcome": "fatal",
    "reporting_source": "FAERS",
    "year": 2023
  },
  {
    "id": "safety-abecma-secmalig-024",
    "text_summary": "Post-marketing data from FAERS and registry studies have identified secondary primary malignancies in 3.8% of idecabtagene vicleucel recipients within 2 years. This includes therapy-related MDS/AML, non-melanoma skin cancers, and solid tumors. Distinguishing CAR-T-related from prior-therapy-related malignancies remains challenging in the heavily pretreated myeloma population. The KarMMa-3 randomized trial (ide-cel vs standard regimens) reported similar secondary malignancy rates in both arms, suggesting confounding by prior therapy exposure (PMID: 36762851).",
    "product": "Abecma (idecabtagene vicleucel)",
    "event_type": "secondary_malignancy",
    "severity_grade": "Grade 3-4",
    "onset_timing": "12-24 months post-infusion",
    "incidence_rate": "3.8% within 2 years; similar rate in KarMMa-3 comparator arm",
    "management_protocol": "Age-appropriate cancer screening; CBC monitoring q3 months for 2 years; skin examination annually; report secondary malignancies to REMS program and FDA MedWatch",
    "outcome": "ongoing",
    "reporting_source": "registry",
    "year": 2023
  },
  {
    "id": "safety-kymriah-bcell-025",
    "text_summary": "B-cell aplasia is an expected on-target, off-tumor effect of CD19-directed CAR-T therapy and serves as a pharmacodynamic biomarker of CAR-T persistence. In ELIANA long-term data, 83% of responding patients maintained B-cell aplasia at 12 months. Resultant hypogammaglobulinemia (IgG <400 mg/dL) required immunoglobulin replacement therapy (IgRT) in 49% of patients. Subcutaneous IgG (SCIg) at 0.1 g/kg/week is preferred over IVIG for outpatient convenience. B-cell recovery with detectable CD19+ cells heralded potential relapse in some patients (PMID: 32439857).",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "organ_toxicity",
    "severity_grade": "Grade 2-3",
    "onset_timing": "Onset within 1 month; persistent in 83% at 12 months in responders",
    "incidence_rate": "83% B-cell aplasia at 12 months; 49% requiring IgRT",
    "management_protocol": "Monthly IgG level monitoring; IgRT (IVIG 400 mg/kg q4 weeks or SCIg 0.1 g/kg/week) for IgG <400 mg/dL with recurrent infections; CD19+ B-cell monitoring for recovery; inactivated vaccines only",
    "outcome": "ongoing",
    "reporting_source": "pivotal_trial",
    "year": 2020
  },
  {
    "id": "safety-yescarta-bcell-026",
    "text_summary": "Long-term immunoglobulin replacement needs following axicabtagene ciloleucel are a significant healthcare utilization concern. A CIBMTR registry analysis of 1,300 patients showed 53% had IgG <400 mg/dL at 1 year, with 38% on active IgRT at 2 years. Total annual IgRT costs averaged $40,000-$80,000 per patient. B-cell recovery occurred in 58% of patients by 2 years, but did not reliably predict freedom from IgRT. Quality-of-life impact assessments showed IgRT burden was rated as moderate-to-significant by 67% of patients (PMID: 35594413).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "organ_toxicity",
    "severity_grade": "Grade 2",
    "onset_timing": "Persistent; 38% on IgRT at 2 years",
    "incidence_rate": "53% hypogammaglobulinemia (IgG <400 mg/dL) at 1 year; 38% on active IgRT at 2 years",
    "management_protocol": "IgG level monitoring q3 months; SCIg preferred for patient autonomy; trough IgG target >500 mg/dL; annual reassessment for IgRT discontinuation if B-cell recovery confirmed with adequate vaccine responses",
    "outcome": "ongoing",
    "reporting_source": "registry",
    "year": 2022
  },
  {
    "id": "safety-breyanzi-bcell-027",
    "text_summary": "B-cell aplasia with lisocabtagene maraleucel showed a distinct kinetic profile in TRANSCEND NHL 001 long-term data. B-cell recovery (CD19+ >1% of lymphocytes) occurred in 60% of patients by 12 months, earlier than with axicabtagene ciloleucel or tisagenlecleucel. This may reflect the defined-composition product design allowing more controlled CAR-T persistence. Immunoglobulin replacement was required in 32% of patients. Patients with early B-cell recovery did not show worse progression-free survival, suggesting anti-tumor efficacy was maintained (PMID: 35030318).",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "event_type": "organ_toxicity",
    "severity_grade": "Grade 1-2",
    "onset_timing": "B-cell aplasia onset within weeks; recovery in 60% by 12 months",
    "incidence_rate": "60% B-cell recovery by 12 months; 32% requiring IgRT",
    "management_protocol": "Monthly B-cell and IgG monitoring; IgRT for symptomatic hypogammaglobulinemia; reassessment of IgRT need upon B-cell recovery; functional antibody response testing before discontinuing IgRT",
    "outcome": "resolved",
    "reporting_source": "pivotal_trial",
    "year": 2022
  },
  {
    "id": "safety-abecma-cardiac-028",
    "text_summary": "Cardiac toxicity with CAR-T therapy, though less common than CRS or ICANS, has emerged as a significant post-market concern. In a retrospective analysis of 137 idecabtagene vicleucel recipients, new cardiac events occurred in 12% within 6 months: atrial fibrillation (5%), heart failure/cardiomyopathy (4%), and troponin elevation (8%). Pre-existing cardiovascular disease and severe CRS were independent risk factors. Cytokine-mediated myocardial injury, particularly via IL-6 and IFN-gamma, is the proposed mechanism (PMID: 36267539).",
    "product": "Abecma (idecabtagene vicleucel)",
    "event_type": "cardiac",
    "severity_grade": "Grade 2-4",
    "onset_timing": "Most within 14 days of CRS onset; some delayed up to 6 months",
    "incidence_rate": "12% any cardiac event; 5% atrial fibrillation; 4% heart failure; 8% troponin elevation",
    "management_protocol": "Baseline echocardiogram and troponin; telemetry monitoring during CRS; serial troponin for grade 2+ CRS; cardiology consultation for LVEF decline >10%; beta-blockers and ACE inhibitors per heart failure guidelines",
    "outcome": "resolved with sequelae",
    "reporting_source": "post_marketing",
    "year": 2022
  },
  {
    "id": "safety-yescarta-cardiac-029",
    "text_summary": "A multi-institutional study of 470 axicabtagene ciloleucel recipients reported cardiovascular events in 17% within 1 year. Grade 3+ cardiac events occurred in 6%, including 3 cases of fatal cardiac arrest during severe CRS. Takotsubo (stress) cardiomyopathy was identified in 1.5% of patients, presenting with acute LV dysfunction and apical ballooning during CRS. Pre-CAR-T cardiovascular risk assessment using the CHA2DS2-VASc score identified high-risk patients for enhanced cardiac monitoring (PMID: 35914404).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "cardiac",
    "severity_grade": "Any grade (17%); Grade 3+ (6%)",
    "onset_timing": "Acute events during CRS (days 2-10); chronic effects up to 12 months",
    "incidence_rate": "17% any cardiovascular event within 1 year; 6% grade 3+; 1.5% Takotsubo cardiomyopathy",
    "management_protocol": "Baseline cardiovascular risk assessment; continuous telemetry for first 10 days; echocardiogram for unexplained tachycardia or hypotension; early tocilizumab to mitigate cytokine-driven cardiac injury",
    "outcome": "resolved with sequelae",
    "reporting_source": "post_marketing",
    "year": 2022
  },
  {
    "id": "safety-carvykti-neuro-030",
    "text_summary": "Delayed neurotoxicity distinct from ICANS has been a class-defining safety signal for BCMA-directed CAR-T products, particularly ciltacabtagene autoleucel. In CARTITUDE-1 updated analysis, movement and neurocognitive treatment-emergent adverse events (MNTs) occurred in 12% of patients: parkinsonism (5%), peripheral neuropathy (4%), cranial nerve palsy (3%), and Guillain-Barre-like syndrome (<1%). Onset ranged from 14 to 210 days post-infusion. The mechanism may involve BCMA expression on neural tissue or anti-neural antibody cross-reactivity (PMID: 37713520).",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "event_type": "neurologic",
    "severity_grade": "Grade 1-4",
    "onset_timing": "14-210 days post-infusion; median 27 days",
    "incidence_rate": "12% MNTs overall; 5% parkinsonism; 4% peripheral neuropathy; 3% cranial nerve palsy",
    "management_protocol": "Extended neurological monitoring q2 weeks for 8 weeks then monthly; MRI brain and spine for new neurological symptoms; neurology consultation mandatory; IVIG and corticosteroids for immune-mediated neuropathy; rehabilitation for persistent deficits",
    "outcome": "resolved with sequelae",
    "reporting_source": "pivotal_trial",
    "year": 2023
  },
  {
    "id": "safety-abecma-neuro-031",
    "text_summary": "Delayed neurotoxicity with idecabtagene vicleucel in KarMMa long-term data included movement and neurocognitive adverse events in 5% of patients. Presentations included peripheral neuropathy (3%), cognitive impairment (2%), and rare cases of Guillain-Barre-like syndrome. These events are distinct from acute ICANS in timing (weeks to months), phenomenology, and proposed mechanism. The FDA REMS program was updated in 2024 to require 6-month neurocognitive monitoring for all BCMA CAR-T recipients (PMID: 36762851).",
    "product": "Abecma (idecabtagene vicleucel)",
    "event_type": "neurologic",
    "severity_grade": "Grade 1-3",
    "onset_timing": "Weeks to months post-infusion; median onset 6 weeks",
    "incidence_rate": "5% movement and neurocognitive adverse events; 3% peripheral neuropathy; 2% cognitive impairment",
    "management_protocol": "Neurocognitive assessment (MoCA) at baseline, 1, 3, and 6 months; nerve conduction studies for neuropathy symptoms; IVIG for suspected immune-mediated neuropathy; physical and occupational therapy referral",
    "outcome": "resolved with sequelae",
    "reporting_source": "pivotal_trial",
    "year": 2023
  },
  {
    "id": "safety-tecartus-neuro-032",
    "text_summary": "Brexucabtagene autoleucel for r/r ALL (ZUMA-3 trial, NCT02614066) showed a unique neurotoxicity profile. Grade 3+ ICANS occurred in 25% of adult ALL patients. Notably, 8% of patients developed delayed encephalopathy beyond day 30, with white matter changes on MRI. Seizures occurred in 5%, necessitating prophylactic levetiracetam. The higher neurotoxicity compared to MCL may reflect ALL disease burden with higher circulating blasts and greater inflammatory cytokine production (PMID: 35085378).",
    "product": "Tecartus (brexucabtagene autoleucel)",
    "event_type": "neurologic",
    "severity_grade": "Grade 3+ (25% ICANS); 8% delayed encephalopathy",
    "onset_timing": "Acute ICANS: days 2-14; delayed encephalopathy: beyond day 30",
    "incidence_rate": "25% grade 3+ ICANS; 8% delayed encephalopathy; 5% seizures",
    "management_protocol": "Mandatory seizure prophylaxis with levetiracetam 500 mg BID starting day -1; EEG for suspected seizures; MRI brain for delayed neurological decline; high-dose corticosteroids and anakinra for refractory neurotoxicity",
    "outcome": "resolved with sequelae",
    "reporting_source": "pivotal_trial",
    "year": 2022
  },
  {
    "id": "safety-yescarta-rw-033",
    "text_summary": "Real-world data from the US Lymphoma CAR-T Consortium (n=275) demonstrated higher rates of severe CRS (18% grade 3+) and ICANS (31% grade 3+) with axicabtagene ciloleucel compared to the ZUMA-1 pivotal trial (13% and 28%, respectively). Older age (>65), higher ECOG performance status (2+), and elevated LDH were associated with worse toxicity in the real-world cohort. Non-relapse mortality at 1 year was 8% in real-world vs 2% in ZUMA-1, predominantly driven by infections and organ toxicity (PMID: 33956076).",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "CRS",
    "severity_grade": "Grade 3+ (18% real-world vs 13% pivotal)",
    "onset_timing": "Similar to pivotal trial; median day 2-3",
    "incidence_rate": "18% grade 3+ CRS (real-world) vs 13% (ZUMA-1); 31% grade 3+ ICANS (real-world) vs 28% (ZUMA-1)",
    "management_protocol": "Enhanced monitoring for patients >65 years; ECOG 2+ patients require ICU-level observation; prophylactic corticosteroids considered for high-risk patients; early tocilizumab intervention",
    "outcome": "resolved",
    "reporting_source": "registry",
    "year": 2021
  },
  {
    "id": "safety-kymriah-rw-034",
    "text_summary": "A CIBMTR registry analysis (n=410) of tisagenlecleucel for adult DLBCL in the real-world setting showed 1-year overall survival of 48% compared to 49% in the JULIET trial, suggesting consistent efficacy. However, grade 3+ CRS was higher at 26% (vs 22% in JULIET) and infection-related mortality was 7% (vs 3%). Patients treated in the real-world were older (median 64 vs 56 years) with more comorbidities (HCT-CI score >3 in 41%). These data support label expansion considerations but highlight the need for enhanced supportive care in community settings (PMID: 34407410).",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "CRS",
    "severity_grade": "Grade 3+ (26% real-world vs 22% pivotal)",
    "onset_timing": "Similar to JULIET pivotal trial timing",
    "incidence_rate": "26% grade 3+ CRS in real-world vs 22% in JULIET; 7% infection-related mortality vs 3%",
    "management_protocol": "Pre-infusion comorbidity assessment with HCT-CI scoring; certified CAR-T center requirements; enhanced antimicrobial prophylaxis for older patients; telemedicine follow-up protocols for community patients",
    "outcome": "resolved",
    "reporting_source": "registry",
    "year": 2021
  },
  {
    "id": "safety-breyanzi-rw-035",
    "text_summary": "Early real-world experience with lisocabtagene maraleucel from 12 US academic centers (n=196) confirmed the favorable safety profile seen in TRANSCEND NHL 001. Grade 3+ CRS occurred in 3% and grade 3+ ICANS in 8%, comparable to pivotal trial rates (2% and 10%). Outpatient CAR-T administration was feasible in 32% of patients, with 87% of outpatient-treated patients avoiding ICU admission. The defined-composition product enabled more predictable toxicity profiles and outpatient administration protocols (PMID: 36481667).",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "event_type": "CRS",
    "severity_grade": "Grade 3+ (3% real-world; 2% pivotal)",
    "onset_timing": "Consistent with pivotal trial; median day 5",
    "incidence_rate": "3% grade 3+ CRS (real-world) vs 2% (pivotal); 8% grade 3+ ICANS (real-world) vs 10% (pivotal)",
    "management_protocol": "Outpatient administration feasible for low-risk patients (low tumor burden, ECOG 0-1, no comorbidities); telemedicine check-ins q12h; same-day readmission pathway for grade 2+ CRS",
    "outcome": "resolved",
    "reporting_source": "registry",
    "year": 2023
  },
  {
    "id": "safety-carvykti-rw-036",
    "text_summary": "Real-world data for ciltacabtagene autoleucel from the CARTITUDE-US expanded access program (n=88) demonstrated grade 3+ CRS in 2.3% and delayed neurotoxicity (MNTs) in 8%, comparable to CARTITUDE-1 (4% and 12%, respectively). However, the real-world population included patients with lower ECOG scores and fewer prior lines of therapy due to the CARTITUDE-4 frontline data. Outpatient monitoring after day 10 was feasible in 55% of patients. Prolonged cytopenias (>60 days) remained a significant challenge at 36% (PMID: 37925840).",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "event_type": "CRS",
    "severity_grade": "Grade 3+ (2.3% real-world vs 4% pivotal)",
    "onset_timing": "Median day 7, consistent with pivotal trial",
    "incidence_rate": "2.3% grade 3+ CRS; 8% MNTs; 36% prolonged cytopenias >60 days in real-world setting",
    "management_protocol": "Outpatient monitoring feasible after day 10 for selected patients; weekly neurocognitive screening for 8 weeks; extended cytopenia monitoring and supportive care",
    "outcome": "resolved",
    "reporting_source": "registry",
    "year": 2024
  },
  {
    "id": "safety-allproducts-rems-037",
    "text_summary": "All six FDA-approved CAR-T products are subject to Risk Evaluation and Mitigation Strategy (REMS) programs requiring certified healthcare facilities and providers. REMS elements include: (1) prescriber training on CRS and ICANS recognition and management, (2) tocilizumab availability within 2 hours at the treatment site, (3) patient monitoring for 7+ days post-infusion, (4) patient wallet card with emergency information. As of 2024, 200+ sites are REMS-certified in the US. REMS audits show 98% compliance with tocilizumab availability and 94% with monitoring requirements.",
    "product": "Kymriah (tisagenlecleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade",
    "onset_timing": "N/A - REMS program requirement",
    "incidence_rate": "N/A - applies to all treated patients",
    "management_protocol": "REMS-certified center requirements: trained physician and healthcare team; minimum 2 doses tocilizumab on-site; ICU access; patient monitoring for minimum 7 days (Yescarta), 7 days (Tecartus), 7 days (Kymriah); patient counseling and wallet card",
    "outcome": "resolved",
    "reporting_source": "label",
    "year": 2024
  },
  {
    "id": "safety-allproducts-boxed-038",
    "text_summary": "In January 2024, FDA mandated updated boxed warnings for all approved CAR-T products to include T-cell malignancies in addition to existing CRS and neurological toxicity warnings. The label update followed identification of 33 cases of T-cell malignancy (including T-cell lymphoma and T-cell leukemia) across all 6 products through FAERS, some confirmed CAR-positive by PCR. The FDA concluded the benefit-risk remains favorable but requires lifelong malignancy monitoring. Product labels now mandate reporting of all secondary T-cell malignancies to the manufacturer and FDA.",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "event_type": "secondary_malignancy",
    "severity_grade": "Grade 5 (fatal)",
    "onset_timing": "Variable; 2 months to 5+ years post-infusion",
    "incidence_rate": "33 cases across ~34,000 total patients treated globally (<0.1%)",
    "management_protocol": "Lifelong monitoring for secondary malignancies; annual CBC, peripheral smear, and LDH; flow cytometry for unexplained lymphocytosis; biopsy of suspicious lesions with CAR transgene PCR analysis; reporting to manufacturer and FDA MedWatch within 15 days",
    "outcome": "fatal",
    "reporting_source": "label",
    "year": 2024
  },
  {
    "id": "safety-allproducts-astct-039",
    "text_summary": "The 2019 ASTCT consensus grading for CRS and ICANS (Lee et al.) standardized adverse event reporting across CAR-T products, replacing product-specific grading scales (Penn, Lee, CTCAE). CRS grading: Grade 1 (fever only), Grade 2 (hypotension responding to fluids or low-dose vasopressors; O2 <40%), Grade 3 (hypotension requiring high-dose vasopressors; O2 >=40%), Grade 4 (life-threatening, ventilator required). ICANS grading based on ICE score: Grade 1 (ICE 7-9), Grade 2 (ICE 3-6), Grade 3 (ICE 0-2), Grade 4 (obtunded). All post-2019 labels adopted ASTCT grading (PMID: 30442462).",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "event_type": "CRS",
    "severity_grade": "Any grade",
    "onset_timing": "N/A - grading system definition",
    "incidence_rate": "N/A - standardized grading applicable to all CAR-T products",
    "management_protocol": "ASTCT consensus grading applied uniformly: Grade 1 CRS - supportive care; Grade 2 - tocilizumab; Grade 3 - tocilizumab + corticosteroids + ICU; Grade 4 - tocilizumab + high-dose corticosteroids + vasopressors + ventilation. ICANS: Grade 1 - monitoring; Grade 2 - dexamethasone; Grade 3-4 - methylprednisolone 1g IV",
    "outcome": "resolved",
    "reporting_source": "label",
    "year": 2019
  },
  {
    "id": "safety-allproducts-labelupdate-040",
    "text_summary": "FDA required a class-wide label update in March 2024 strengthening warnings for prolonged and recurrent cytopenias across all CAR-T products. The updated Warnings and Precautions section now includes recommended monitoring: CBC with differential at baseline, weekly for 4 weeks, then monthly for 6 months. The update was prompted by post-marketing reports of fatal infections secondary to prolonged neutropenia and cases of aplastic anemia requiring stem cell rescue. Additionally, labels were updated to recommend hematology consultation for cytopenias persisting beyond 90 days (FDA Label Supplement, March 2024).",
    "product": "Tecartus (brexucabtagene autoleucel)",
    "event_type": "cytopenia",
    "severity_grade": "Grade 3-4",
    "onset_timing": "Persistent beyond 30 days per updated label definition",
    "incidence_rate": "30-40% prolonged cytopenias across products; rare aplastic anemia requiring stem cell rescue",
    "management_protocol": "CBC with differential: weekly x4 weeks then monthly x6 months per updated label; G-CSF per institutional guidelines; hematology referral for cytopenias >90 days; bone marrow biopsy to assess cellularity; autologous or allogeneic stem cell rescue for refractory aplasia",
    "outcome": "resolved",
    "reporting_source": "label",
    "year": 2024
  }
]
